Esperion Therapeutics
ESPR
ESPR was delisted on the 10th of July, 2026.
102 hedge funds and large institutions have $200M invested in Esperion Therapeutics in 2016 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 30 increasing their positions, 28 reducing their positions, and 16 closing their positions.
35% more capital invested
Capital invested by funds: $148M → $200M (+$52.1M)
32% more call options, than puts
Call options by funds: $2.74M | Put options by funds: $2.08M
7% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 28
0% more funds holding
Funds holding: 102 → 102 (0)
0% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$3.61M |
| 2 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$3.4M |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$1.91M |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$1.05M |
| 5 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
+$850K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.43M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$2.76M |
| 3 |
VOYA Investment Management
Atlanta,
Georgia
|
-$2.74M |
| 4 |
FMA
FNY Managed Accounts
New York
|
-$2.27M |
| 5 |
SAM
Senzar Asset Management
New York
|
-$2.17M |
ESPR Hedge Fund Activity: Q3 2016 in Review
102 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Esperion Therapeutics (ESPR) for Q3 2016, worth a combined $200M — up 35% from $148M a quarter earlier.
Fund positioning in ESPR was balanced in Q3 2016: 16 funds opened new positions, 16 closed out, 30 added to existing stakes and 28 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $3.61M. The largest seller was Fidelity Investments, cutting an estimated $3.43M.
- 102 institutional investors held Esperion Therapeutics (ESPR) as of Q3 2016, unchanged from Q2 2016.
- Funds reported $200M of Esperion Therapeutics stock for Q3 2016, up 35% quarter-over-quarter.
- 16 funds opened new Esperion Therapeutics positions in Q3 2016 and 16 closed out, a net change of 0 holders.
- The largest Esperion Therapeutics buyer in Q3 2016 was Renaissance Technologies, an estimated $3.61M added.
- The largest Esperion Therapeutics seller in Q3 2016 was Fidelity Investments, an estimated $3.43M sold.
Based on aggregated 13F filings for Q3 2016.